Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

Other research analysts also recently issued research reports about the stock. Oppenheimer reiterated a “buy” rating on shares of Sarepta Therapeutics in a research note on Monday, September 25th. SunTrust Banks reiterated a “buy” rating and issued a $56.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, September 7th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, September 6th. Nomura restated a “buy” rating and set a $84.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, September 5th. Finally, Instinet restated a “buy” rating and set a $84.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $64.14.

Sarepta Therapeutics (NASDAQ SRPT) opened at $55.05 on Tuesday. Sarepta Therapeutics has a 12 month low of $26.26 and a 12 month high of $57.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The company had revenue of $45.95 million during the quarter, compared to the consensus estimate of $41.29 million. During the same quarter in the previous year, the firm earned ($0.95) earnings per share. equities analysts expect that Sarepta Therapeutics will post -3.11 EPS for the current fiscal year.

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the business’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the transaction, the director now directly owns 13,333 shares of the company’s stock, valued at approximately $745,181.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Shamim Ruff sold 11,500 shares of the business’s stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $50.00, for a total transaction of $575,000.00. The disclosure for this sale can be found here. Insiders sold a total of 28,167 shares of company stock worth $1,497,619 over the last ninety days. Corporate insiders own 9.60% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in SRPT. Jennison Associates LLC increased its stake in Sarepta Therapeutics by 103.9% in the 3rd quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock valued at $51,885,000 after buying an additional 582,894 shares during the period. Alyeska Investment Group L.P. acquired a new position in Sarepta Therapeutics in the 3rd quarter valued at $26,011,000. Voya Investment Management LLC increased its stake in Sarepta Therapeutics by 2,786.1% in the 2nd quarter. Voya Investment Management LLC now owns 568,525 shares of the biotechnology company’s stock valued at $19,165,000 after buying an additional 548,826 shares during the period. Gilder Gagnon Howe & Co. LLC increased its stake in Sarepta Therapeutics by 3,599.4% in the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 534,087 shares of the biotechnology company’s stock valued at $24,226,000 after buying an additional 519,650 shares during the period. Finally, HealthCor Management L.P. increased its stake in Sarepta Therapeutics by 31.1% in the 2nd quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock valued at $68,495,000 after buying an additional 481,890 shares during the period. 82.02% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.watchlistnews.com/sarepta-therapeutics-srpt-rating-lowered-to-hold-at-bidaskclub/1775794.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.